ADC Development Services Targeting CD25

As a class of novel cancer therapeutics with antigen specificity and potent cytotoxicity, Antibody-drug conjugates (ADCs) are developed actively. Creative Biolabs provides a full range of ADC construction services from antibody discovery and drug production to ADC conjugation. In addition, we have innovative linker and linker-payload technologies to improve the homogeneity, PK/PD and efficacy of ADC drugs. We are confident to boost your ADC development with our experienced scientists and state-of-the-art facilities.

Introduction of CD25

CD25, also known as interleukin-2 receptor alpha chain (IL-2R1), is encoded by the IL2RA gene in human. It is a 55 kDa single-chain transmembrane glycoprotein. The receptor can interact with IL-2 (IL-2Ra) with low affinity, while it can produce a high-affinity IL-2R complex after combining with p75 beta-chain (CD122 antigen, IL-2Rb). CD25 mainly presents on activated T and B cells, activated macrophages, T cell clones and NK cells. As a receptor, it plays a critical role in recognizing the HTLV-1, and it is also an important marker used in identified CD4⁺FoxP3⁺ regulatory T cells in mice. It is a marker of memory T cells and lymphoma cells in human. Thus, CD25 is a target used in cancer treatment such as the Hodgkin lymphoma and non-Hodgkin lymphoma (NHL).

Fig.1 Pathways of activation of naïve CD4+CD25+T regulatory cell (Treg) (tTreg). ^1,2

Anti-CD25 ADC for Lymphoma

Compared to conventional medicines' poor outcomes for the treatment of refractory lymphomas, ADCs are becoming potential and promising therapeutic agents. CD25 is overexpressed on many lymphoma cells such as the HL and NHL, which is regarded as a target in ADCs development.

What Can We Do for You?

Creative Biolabs has long-term devoted to the development of ADCs and we have finished lots of projects based on our extensive experience. Creative Biolabs is confident in offering the best ADCs services and products targeting CD25 for our customers all over the world. If you are interested in our service, please do not hesitate to contact us for more details.

Our ADCs development services including but not limited to:

• ADC Antibody Screening
• DrugLnk™ Custom Synthesis
• Antibody Design and Conjugation
• ADC in vitro Analysis
• ADC in vivo Analysis

References

1. Hall, Bruce M., et al. "Changes in reactivity in vitro of CD4+ CD25+ and CD4+ CD25− T cell subsets in transplant tolerance." Frontiers in immunology 8 (2017): 994..
2. Distributed under Open Access License CC BY 4.0, without modification.